Product
IVIG-PEG
1 clinical trial
1 indication
Indication
Primary ImmunodeficiencyClinical trial
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral ImmunodeficiencyStatus: Completed, Estimated PCD: 2022-03-28